We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of QIAGEN N.V. (“QIAGEN” or the “Company”) (NYSE: QGEN) to Thermo Fisher Scientific Inc. (“Thermo Fisher”) (NYSE: TMO) . Under the terms of the merger, Thermo Fisher will acquire all ordinary shares of QIAGEN at an offer price of €39 per share in cash.
The QIAGEN merger investigation concerns whether the Board of QIAGEN has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
To receive more information, please fill out the form.